BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 14, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» HIF-1α inhibitors revealed in Nextgen Bioscience patent
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
HIF-1α inhibitors revealed in Nextgen Bioscience patent
Feb. 8, 2024
No Comments
Work at Nextgen Bioscience Co. Ltd. has led to the development of purine derivatives acting as hypoxia-inducible factor 1α (HIF-1α) inhibitors.
BioWorld Science
Neurology/psychiatric
Patents